Collectively, these data highlight the ability of DNA-PK inhibition to elicit the activation of a unique group of tumor-reactive CD8+ T cells, increase the diversity of tumor-specific TCRvβ family members, and enhance the production of cytotoxic molecules. The gene discussed is PRKDC; the disease is neoplasm.